The size of the Europe Migraine Drugs Market is estimated to worth USD 1.22 billion in 2022 and estimated to be growing at a CAGR of 4.44 % to reach USD 1.52 billion by 2027. Migraines are a source of both lost productivity and medical costs. The European market is the second-largest migraine drug market in the world. Growing patient population and escalating awareness among the patients relevant to the control and treatment of migraine are accelerating the market growth. UK, Germany, and France are the major contributors to the European region's migraine drug market.
The growing aging population and rising incidence rate of migraine in Europe are majorly driving the migraine market in Europe during the forecast period. Enhancements in the reimbursement policies associated with the medications and increasing awareness in people by organizing programs are favorable factors to the market growth. The unmet needs and growing R&D investments are further expected to support the market during the forecast period.
High investments required for the R&D for the drug discovery and strict regulations made by the governments towards the migraine headache are the restraining factors the market growth. Repercussions associated with the usage of migraine drugs may restrict market growth during the analysis period.
This research report on the European Migraine Drugs Market has been segmented and sub-segmented into the following categories:
By Therapeutic Class:
Regionally, the UK's migraine drug market is expected to lead the European market due to the growing patient population, changes in lifestyle, rising endorsement of new drug classes, and the invention of peptide-based therapies for the medication of migraine. Around 900,000 adults in the UK are suffering from chronic migraines. The market key players operating in the UK market are coming with the product and new drug launches and strategic collaborations to toughen their market status.
The Germany Migraine Drugs Market is expected to hike at a favorable CAGR from 2020 to 2025. Approval of the new drugs manufactured to treat migraine headaches, the presence of key players like Pfizer, Eli Lilly, and many more are driving the market. Moreover, the FDA approvals of novel drugs by the key players in the market accelerate the region's growth.
France and Italy are expected to have strong growth in the upcoming years. High uncovering to screens and pressurized lifestyle, and the existence of product pipeline are to provide support to the market in having robust growth over the upcoming years.
Key players operating in the Europe Migraine Drugs Market profiled in this report are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories. The other prominent vendors the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pfizer, Pozen, Eisai, Raptor, RedHill, SUDA, Teva, Aegis Therapeutics, Merck, TG Therapeutics, NValeant, Winston Pharmaceuticals, Allergan, and Zogenix.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org